NEWARK, N.J., Nov. 10, 2016 /PRNewswire/ -- Symbiomix, a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections, today announced that Symbiomix President and CFO Robert Jacks will provide a company overview at Jefferies 2016 London Healthcare Conference in London on November 17, 2016 at 4:40 p.m. GMT.
About Symbiomix Therapeutics, LLC
Symbiomix (sim-bye-OH-mix) is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecological infections that can have serious health consequences. The Company's lead investigational drug Solosec™ (secnidazole) oral granules, a potent, next-generation 5-nitroimidazole antibiotic, is anticipated to be the first and only single-dose oral treatment approved for bacterial vaginosis (BV). Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world's leading healthcare venture capital firms: OrbiMed, F-Prime Capital Partners, and HBM Partners. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut. Please visit www.symbiomix.com and follow the Company on LinkedIn and Twitter for more information.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/symbiomix-to-present-at-jefferies-2016-london-healthcare-conference-300360446.html
SOURCE Symbiomix Therapeutics, LLC